丨 2025年12月2日星期二丨 NO.1 复宏汉霖PD-L1 ADC II期结果读出 11月26日, 复宏汉霖发布公告表示将在ESMO Asia 2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1 ADC药物HLX43在宫颈癌领域的II期研究结果。 点评:针对PD-L1 ADC开发在研管线并不多,目前进度最快的是辉瑞的PF-08046054,已至临床III期。除此之外,...
Source Link丨 2025年12月2日星期二丨 NO.1 复宏汉霖PD-L1 ADC II期结果读出 11月26日, 复宏汉霖发布公告表示将在ESMO Asia 2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1 ADC药物HLX43在宫颈癌领域的II期研究结果。 点评:针对PD-L1 ADC开发在研管线并不多,目前进度最快的是辉瑞的PF-08046054,已至临床III期。除此之外,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.